Dalbavancin has been utilized for long-term suppressive antibiotic therapy for complicated gram-positive infections in certain patients with limited treatment options.Dalbavancin is a lipoglycopeptide, and like other glycopeptides it inhibits bacterial cell wall synthesis in gram-positive organisms by binding to the D-alanyl-D-alanine terminus of peptidoglycan precursors. Although dalbavancin’s only FDA labeled indication is acute bacterial skin and soft tissue infections, it…
Source: Healio News
